Description
The U.S. Army Contracting Command - Joint COVID-19 Response Division, 6472 Integrity Court (Building 4401), Aberdeen Proving Ground, MD 21005-3013 has a sole source requirement on behalf of the Department of Health and Human Services (DHHS) (collectively, the Government or USG) to procure up to 3.7 million treatment courses (TC) of Pfizer-s oral antiviral therapeutic, PAXLOVID, to treat the US general population in response to the SAR-CoV-2 Virus.
This acquisition will be conducted as a sole source contract to Pfizer Inc., 235 E. 42nd St, New York, New York, 10017-5703, IAW FAR 6.302-1. The USG anticipates awarding a firm fixed price contract modification with a period of performant of 81 months. Interested parties who believe they have a basis for providing Pfizer-s oral antiviral therapeutic PAXLOVID product, or have other questions pertaining to this acquisition, may contact Danny Soto at
[email protected] and Robin Bronson at
[email protected]Active Contract Opportunity
Notice ID : W58P0522C0001P00005
Related Notice
Department/Ind. Agency : DEPT OF DEFENSE
Sub-tier : DEPT OF THE ARMY :
General Information
Contract Opportunity Type: Special Notice (Original)
All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
Original Published Date: Nov 02, 2022 01:28 pm EDT
Original Response Date: Nov 09, 2022 03:00 pm EST
Inactive Policy: 15 days after response date
Original Inactive Date:
Initiative: None
Classification
Original Set Aside:
Product Service Code: 6505 - DRUGS AND BIOLOGICALS
NAICS Code: 325412 - Pharmaceutical Preparation Manufacturing
Place of Performance: New York, NY 10017 USA